Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12613000297729
ACTRN12613000297729
Terminated
Phase 1

A Phase 1/2 study to determine the effect of EGFR targeted Doxorubicin loaded EnGeneIC Delivery Vehicles (VEDVDox) on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM) Expressing Epidermal Growth Factor Receptor (EGFR)

EnGeneIC Ltd0 sites46 target enrollmentMarch 18, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRecurrent Glioblastoma MultiformeCancer - Brain

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Recurrent Glioblastoma Multiforme
Sponsor
EnGeneIC Ltd
Enrollment
46
Status
Terminated
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 18, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients with pathologically documented, and definitively diagnosed recurrent WHO Grade IV advanced malignant GBM which expresses EGFR.

Exclusion Criteria

  • •Previous treatment with bevacizumab or anti\-angiogenic therapy, treatment with immunotherapeutic agents, vaccines, or monoclonal antibody in past 4 weeks. Known allergy or sensitivity to any of the excipients in the investigational product

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Study of association between effect of first EGFR-TKI for EGFR-mutated non-small cell lung cancer and circulating tumor DNA detected with high sensitive analyses for EGFR mutation.
JPRN-UMIN000014092Miyagi CancerCenter30
Unknown
Phase 2
Panitumumab Skin Toxicity Prevention TrialColorectal Cancer MetastaticSkin Toxicity
NCT03167268Ospedale San Carlo Borromeo28
Active, not recruiting
Phase 1
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-004482-14-DEovartis Pharma Services AG500
Active, not recruiting
Phase 1
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 17.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-004482-14-ESovartis Farmacéutica, S.A.211
Active, not recruiting
Phase 1
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-004482-14-NLovartis Pharma Services AG211